Dailypharm Live Search Close

Reimb for Verzenio in early breast cancer undergoes review

By Eo, Yun-Ho | translator Kim, Jung-Ju

24.03.05 17:12:29

°¡³ª´Ù¶ó 0
Second attempt since failing to set reimbursement standards the past year

Confirmed additional benefit through 5-year monarchE data


Verzenio, the first CDK4/6 inhibitor to apply for insurance reimbursement in early breast cancer, is taking the second step to extend its reimbursement coverage.

According to a report, the agenda of reimbursing Lilly Korea¡¯s Verzenio (abemaciclib) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (March 6).

Therefore, the industry¡¯s attention is on whether Verzenio will succeed in its second reimbursement attempt.

The company had difficulty reaching the CDDC stage during its first attempt for reimbursement in early breast cancer. After a long 6-month wait after submitting the application, the case reache

Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)